ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Institut Curie at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Institut Curie takes part in 26 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8042. Its program connects cancer biomarkers and treatment strategies across breast, lung and other cancers. It examines circulating tumour DNA for detecting relapse in HPV-related pelvic cancer and treatment approaches for metastatic uveal melanoma.
| Organization | ESMO 2026 Attendance |
|---|---|
Institut Curie Paris, France | |
Private non-profit cancer centre in Paris, France, combining a research centre with hospital sites. | Booth Exhibiting at Booth 8042 Satellite Fri Oct 23 09:50–10:15 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Clinical utility of HPV circulating tumor DNA in anal cancer: Real-world data from a French high-volume center Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 French recommendations on multigene panel testing in pancreatic ductal adenocarcinoma Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 HER2 IHC expression across multiple solid tumor types: Insights from the ESPERANZA Programme Biomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 SWI/SNF-deficient tumors define a distinct subset of cancers of unknown primary: Data from the French National CUP cohort Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Tebentafusp discontinuation after sustained disease control in metastatic uveal melanoma (mUM): A single-center ambispective observational study Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Tumor-bound factor H controls complement activation and is a potential therapeutic target in oral cavity and HPV-negative oropharyngeal squamous cell carcinoma Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 ctDNA and survival outcomes in first-line ICI-treated metastatic NSCLC-interim analysis Lung & thoracic cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 An in-depth multistate analysis of a national multidisciplinary tumour board (MTB) for patients with cancer of unknown primary Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Comprehensive genomic profiling in lacrimal duct carcinoma reveals HER2-driven biology and emerging therapeutic targets Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Integrated clinical and transcriptomic biomarkers predict survival and immune checkpoint inhibitor response in cancers of unknown primary Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 MTAP loss and HPV status in head and neck squamous cell carcinoma (HNSCC): A genomic landscape study Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Satellite Fri Oct 23 18:15–19:45 Satellite Fri Oct 23 18:15–18:20 Welcome Melanoma & skin cancers Satellite Fri Oct 23 19:15–19:40 Interactive Case and Panel Discussion: Applying Evidence to Practice Melanoma & skin cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Darovasertib with crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma (OptimUM-02): A subgroup analysis Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 PLUME: Overall survival results from a phase II trial of pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with metastatic uveal melanoma (mUM) Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 13:05–13:35 Maximizing 1L outcomes in HR+ mBC Breast cancer Talk Sat Oct 24 17:00–17:15 How to monitor biomarkers and ctDNA Breast cancerBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Satellite Sun Oct 25 13:20–14:05 Neoadjuvant vs Perioperative Immunotherapy: An Expert Clinical Debate Lung & thoracic cancers Satellite Sun Oct 25 14:05–14:25 Looking To the Future: How Emerging Strategies Could Address Unmet Needs in NSCLC Lung & thoracic cancers Talk Sun Oct 25 15:25–15:45 Toxicities of cytokines and intratumoral immunotherapies Nursing & supportive care Chair Sun Oct 25 18:30–20:00 Talk Sun Oct 25 19:25–19:45 Ongoing research and horizon scanning in cancer with ROS1 rearrangements Lung & thoracic cancers Talk Mon Oct 26 09:30–09:50 Poster Mon Oct 26 12:00–12:45 Epigenomic priming shapes chemoresistant tumor states in high-grade serous ovarian cancer Gynaecological cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 ctDNA for early detection of HPV-induced pelvic cancer relapse: A multicentric prospective study Gastrointestinal cancersGynaecological cancersBiomarkers & precision oncology |
Find decision makers at Institut Curie
Tell us what you sell and we’ll find the people at Institut Curie most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction